Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon α-2b for the treatment of chronic myelogenous leukemia patients in chronic phaseMALOISEL, F; GUERCI, A; ABGRALL, J. F et al.Leukemia. 2002, Vol 16, Num 4, pp 573-580, issn 0887-6924Article

Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantroneBRAESS, J; KERN, W; UNTERHALT, M et al.Annals of hematology (Print). 1996, Vol 73, Num 4, pp 201-204, issn 0939-5555Article

A phase II study of α-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemiaROSTI, G; BONIFAZI, F; TRABACCHI, E et al.Leukemia. 2003, Vol 17, Num 3, pp 554-559, issn 0887-6924, 6 p.Article

Participation of the peroxisomal β-oxidation system in the chain-shortening of PCA₁6, a metabolite of the cytosine arabinoside prodrug, YNK01, in rat liverYOSHIDA, Y; YAMADA, J; WATANABE, T et al.Biochemical pharmacology. 1990, Vol 39, Num 10, pp 1505-1512, issn 0006-2952Article